Aelis Farma
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
AELIS | PA
Overview
Corporate Details
- ISIN(s):
- FR0014007ZB4
- LEI:
- 8945008D5R6WV7EXRN47
- Country:
- France
- Address:
- 1 RUE LAFAURIE DE MONBADON, 33000 BORDEAUX
- Website:
- https://www.aelisfarma.com
- Sector:
- Manufacturing
Description
Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-28 17:45 |
Informations privilégiées / Autres communiqués
|
French | 288.3 KB | ||
| 2023-07-20 17:45 |
Inside Information / Other news releases
|
English | 278.0 KB | ||
| 2023-07-20 17:45 |
Informations privilégiées / Autres communiqués
|
French | 291.3 KB | ||
| 2023-07-05 07:00 |
Inside Information / Other news releases
|
English | 277.8 KB | ||
| 2023-07-05 07:00 |
Informations privilégiées / Autres communiqués
|
French | 288.2 KB | ||
| 2023-07-04 18:03 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 406.6 KB | ||
| 2023-07-03 17:45 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 238.2 KB | ||
| 2023-06-21 18:00 |
Acquisition or disposal of the issuer's own shares / Description of the buyback…
|
English | 248.7 KB | ||
| 2023-06-21 18:00 |
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de r…
|
French | 244.9 KB | ||
| 2023-06-12 07:00 |
Informations privilégiées / Autres communiqués
|
French | 298.5 KB | ||
| 2023-06-12 07:00 |
Inside Information / Other news releases
|
English | 289.3 KB | ||
| 2023-06-08 17:15 |
Informations privilégiées / Autres communiqués
|
French | 337.5 KB | ||
| 2023-06-08 17:15 |
Inside Information / Other news releases
|
English | 328.4 KB | ||
| 2023-06-05 18:52 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 233.4 KB | ||
| 2023-05-25 18:00 |
Informations privilégiées / Autres communiqués
|
French | 243.5 KB |
Automate Your Workflow. Get a real-time feed of all Aelis Farma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aelis Farma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aelis Farma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
